JP5711118B2 - 所与の標的に対してアフィニティーを有するｈＮＧＡＬおよび類縁タンパク質のムテイン - Google Patents

所与の標的に対してアフィニティーを有するｈＮＧＡＬおよび類縁タンパク質のムテイン Download PDF

Info

Publication number
JP5711118B2
JP5711118B2 JP2011514065A JP2011514065A JP5711118B2 JP 5711118 B2 JP5711118 B2 JP 5711118B2 JP 2011514065 A JP2011514065 A JP 2011514065A JP 2011514065 A JP2011514065 A JP 2011514065A JP 5711118 B2 JP5711118 B2 JP 5711118B2
Authority
JP
Japan
Prior art keywords
leu
thr
gln
ala
hngal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2011514065A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011525354A (ja
JP2011525354A5 (enExample
Inventor
スケラ，アルネ
アイヒンガー，アンドレアス
キム，ヒュン−ジン
Original Assignee
テクニッシュ ウニヴェルジテート ミュンヘン
テクニッシュ ウニヴェルジテート ミュンヘン
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by テクニッシュ ウニヴェルジテート ミュンヘン, テクニッシュ ウニヴェルジテート ミュンヘン filed Critical テクニッシュ ウニヴェルジテート ミュンヘン
Publication of JP2011525354A publication Critical patent/JP2011525354A/ja
Publication of JP2011525354A5 publication Critical patent/JP2011525354A5/ja
Application granted granted Critical
Publication of JP5711118B2 publication Critical patent/JP5711118B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/081—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the protein being an albumin, e.g. human serum albumin [HSA], bovine serum albumin [BSA], ovalbumin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Optics & Photonics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Toxicology (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2011514065A 2008-06-24 2009-06-24 所与の標的に対してアフィニティーを有するｈＮＧＡＬおよび類縁タンパク質のムテイン Active JP5711118B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US7517508P 2008-06-24 2008-06-24
US61/075,175 2008-06-24
PCT/EP2009/057925 WO2009156456A1 (en) 2008-06-24 2009-06-24 Muteins of hngal and related proteins with affinity for a given target

Publications (3)

Publication Number Publication Date
JP2011525354A JP2011525354A (ja) 2011-09-22
JP2011525354A5 JP2011525354A5 (enExample) 2014-12-04
JP5711118B2 true JP5711118B2 (ja) 2015-04-30

Family

ID=41256028

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011514065A Active JP5711118B2 (ja) 2008-06-24 2009-06-24 所与の標的に対してアフィニティーを有するｈＮＧＡＬおよび類縁タンパク質のムテイン

Country Status (7)

Country Link
US (2) US8420051B2 (enExample)
EP (2) EP2313430B1 (enExample)
JP (1) JP5711118B2 (enExample)
AU (1) AU2009264214B2 (enExample)
CA (1) CA2729322C (enExample)
DK (1) DK3381933T3 (enExample)
WO (1) WO2009156456A1 (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006115633A2 (en) 2005-04-22 2006-11-02 University Of Washington Cyanine-chlorotoxin conjugate and method for intra-operative fluorescent visualization of cancer
WO2009140599A1 (en) 2008-05-15 2009-11-19 Transmolecular, Inc. Treatment of metastatic tumors
EP2313430B1 (en) * 2008-06-24 2018-05-02 Technische Universität München Muteins of hngal and related proteins with affinity for a given target
EP2990798B1 (en) * 2009-12-07 2019-09-25 Pieris Pharmaceuticals GmbH Muteins of human lipocalin 2 (lcn2, hngal) with affinity for a given target
CN106995493B (zh) 2010-02-04 2021-09-24 卫材公司 氯毒素多肽和结合物及其应用
ES2601182T3 (es) 2010-05-11 2017-02-14 Fred Hutchinson Cancer Research Center Variantes de clorotoxina, conjugados y métodos para su utilización
JP2013529907A (ja) * 2010-05-24 2013-07-25 ザ トラスティーズ オブ コロンビア ユニヴァーシティ イン ザ シティ オブ ニューヨーク Ｎｇａｌタンパク質変異体及びその使用
AU2011290751B2 (en) * 2010-08-16 2015-08-13 Pieris Ag Binding proteins for Hepcidin
CA2817779C (en) * 2010-11-15 2019-02-19 Pieris Ag Muteins of human lipocalin 2 with affinity for glypican-3 (gpc3)
US9758554B2 (en) 2012-01-31 2017-09-12 Technische Universitaet Muenchen Muteins of α1m lipocalin and method of production therefor
US20140122522A1 (en) * 2012-10-26 2014-05-01 Google Inc. Method for providing users with help from their contacts while searching the web
WO2014081980A2 (en) 2012-11-21 2014-05-30 The Trustees Of Columbia University In The City Of New York Mutant ngal proteins and uses thereof
CN105189540A (zh) 2012-12-10 2015-12-23 弗莱德哈钦森癌症研究中心 含脂质运载蛋白融合伴侣
CA2891557A1 (en) 2013-03-26 2014-05-22 Pieris Ag Novel specific-binding polypeptides and uses thereof
US11559580B1 (en) 2013-09-17 2023-01-24 Blaze Bioscience, Inc. Tissue-homing peptide conjugates and methods of use thereof
EP3102224B1 (en) 2013-12-20 2019-02-20 NephroGenesis, LLC. Apparatuses for kidney dialysis and lipocalin protein for use in the prevention or treatment of uremia by dialysis
AU2015261968B2 (en) 2014-05-22 2018-11-22 Pieris Pharmaceuticals Gmbh Novel specific-binding polypeptides and uses thereof
MX384075B (es) * 2015-01-28 2025-03-14 Pieris Pharmaceuticals Gmbh Nuevas proteínas específicas para la angiogénesis.
WO2016131804A1 (en) 2015-02-18 2016-08-25 Sanofi Novel proteins specific for pyoverdine and pyochelin
CN114316067A (zh) * 2015-05-04 2022-04-12 皮里斯制药有限公司 抗癌融合多肽
ES2932425T3 (es) 2015-05-04 2023-01-19 Pieris Pharmaceuticals Gmbh Proteínas específicas para CD137
MX390894B (es) 2015-05-18 2025-03-21 Pieris Pharmaceuticals Gmbh Polipéptido de fusión anti-cáncer.
BR112017020961A2 (pt) 2015-05-18 2018-07-10 Pieris Pharmaceuticals Gmbh muteína, molécula de ácido nucleico, célula hospedeira, método de produção de uma muteína e método de ligação
EP3115371A1 (en) 2015-07-07 2017-01-11 Sanofi Fusion molecules
EP3115066A1 (en) 2015-07-07 2017-01-11 Technische Universität München Novel psma-specific binding proteins
SG10201911499TA (en) 2015-11-30 2020-01-30 Pieris Australia Pty Ltd Novel anti-angiogenic fusion polypeptides
TW201725212A (zh) * 2015-12-10 2017-07-16 第一三共股份有限公司 特異性於降鈣素基因相關胜肽的新穎蛋白
CA3021011A1 (en) 2016-04-15 2017-10-19 Blaze Bioscience, Inc. Methods of treating breast cancer
CA3022751A1 (en) * 2016-05-04 2017-11-09 Navigo Proteins Gmbh Targeted compounds for the site-specific coupling of chemical moieties comprising a peptide linker
ES3015117T3 (en) 2016-08-29 2025-04-29 Fred Hutchinson Cancer Center Chelating platform for delivery of radionuclides

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01215289A (ja) 1988-02-22 1989-08-29 Toa Nenryo Kogyo Kk 遺伝子組換えによる正常ヒト血清アルブミンａの製造方法
FR2649991B2 (fr) 1988-08-05 1994-03-04 Rhone Poulenc Sante Utilisation de derives stables du plasmide pkd1 pour l'expression et la secretion de proteines heterologues dans les levures du genre kluyveromyces
US5124471A (en) 1990-03-26 1992-06-23 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Bifunctional dtpa-type ligand
US5756825A (en) 1992-09-08 1998-05-26 Safavy; Ahmad Hydroxamic acid-based bifunctional chelating compounds
US5728553A (en) 1992-09-23 1998-03-17 Delta Biotechnology Limited High purity albumin and method of producing
US5908621A (en) 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
US6620413B1 (en) 1995-12-27 2003-09-16 Genentech, Inc. OB protein-polymer chimeras
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
CA2233725A1 (en) 1998-03-31 1999-09-30 Hemosol Inc. Hemoglobin-hydroxyethyl starch complexes
DK1087778T3 (da) 1998-06-08 2005-12-19 Hoffmann La Roche Anvendelse af PEG-IFN-alfa og Ribavirin til behandling af kronisk hepatitis C
US6403564B1 (en) 1998-10-16 2002-06-11 Schering Corporation Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection
DE19926068C1 (de) 1999-06-08 2001-01-11 Arne Skerra Muteine des Bilin-Bindungsproteins
CA2440582A1 (en) 2001-03-09 2002-10-03 Dyax Corp. Serum albumin binding moieties
WO2003029462A1 (en) 2001-09-27 2003-04-10 Pieris Proteolab Ag Muteins of human neutrophil gelatinase-associated lipocalin and related proteins
US7118915B2 (en) 2001-09-27 2006-10-10 Pieris Proteolab Ag Muteins of apolipoprotein D
WO2005019255A1 (en) 2003-08-25 2005-03-03 Pieris Proteolab Ag Muteins of tear lipocalin
WO2005019254A1 (en) 2003-08-25 2005-03-03 Pieris Proteolab Ag Muteins of a bilin-binding protein with affinity for a given target
US7517508B2 (en) 2004-07-26 2009-04-14 Isoray Medical, Inc. Method of separating and purifying Yttrium-90 from Strontium-90
US7892827B2 (en) 2004-11-26 2011-02-22 Pieris Ag Compound with affinity for the cytotoxic T lymphocyte-associated antigen (CTLA-4)
US20070191272A1 (en) 2005-09-27 2007-08-16 Stemmer Willem P Proteinaceous pharmaceuticals and uses thereof
EP2313430B1 (en) * 2008-06-24 2018-05-02 Technische Universität München Muteins of hngal and related proteins with affinity for a given target

Also Published As

Publication number Publication date
AU2009264214A1 (en) 2009-12-30
CA2729322A1 (en) 2009-12-30
US20130316962A1 (en) 2013-11-28
AU2009264214B2 (en) 2013-06-06
EP3381933A1 (en) 2018-10-03
EP3381933B1 (en) 2020-06-03
WO2009156456A1 (en) 2009-12-30
DK3381933T3 (da) 2020-08-03
US20110262353A1 (en) 2011-10-27
US8420051B2 (en) 2013-04-16
EP2313430B1 (en) 2018-05-02
CA2729322C (en) 2020-05-26
JP2011525354A (ja) 2011-09-22
EP2313430A1 (en) 2011-04-27
US9040020B2 (en) 2015-05-26

Similar Documents

Publication Publication Date Title
JP5711118B2 (ja) 所与の標的に対してアフィニティーを有するｈＮＧＡＬおよび類縁タンパク質のムテイン
JP6346159B2 (ja) 所定の標的に対して親和性を有するヒトリポカリン２（Ｌｃｎ２、ｈＮＧＡＬ）の突然変異タンパク質
JP5608368B2 (ja) 涙リポカリンの突然変異タンパク質およびそれを得るための方法
US11628222B2 (en) CD71 binding fibronectin type III domains
US20190184028A1 (en) Targeting with firbronectin type iii like domain molecules
JP2018519802A (ja) グリピカン−３（ｇｐｃ３）に対する親和性を有するヒトリポカリン２のムテイン
US20250129137A1 (en) Cd71 binding fibronectin type iii domains
US20090274623A1 (en) In vivo imaging agents for met receptor tyrosine kinase
AU2013224694B2 (en) MUTEINS OF hNGAL AND RELATED PROTEINS WITH AFFINITY FOR A GIVEN TARGET
CN117616045A (zh) 结合cd71的纤连蛋白iii型结构域
AU2011203057B2 (en) Muteins of tear lipocalin and methods for obtaining the same
HK40076447B (zh) 结合cd71的纤维粘连蛋白iii型结构域
HK40076447A (en) Cd71 binding fibronectin type iii domains

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120524

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120524

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140121

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140416

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140423

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140516

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20140516

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20140617

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20141016

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20141017

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20150106

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20150203

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20150305

R150 Certificate of patent or registration of utility model

Ref document number: 5711118

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250